74256-73-8

Basic information

• Product Name: 3,6'-bis(N-benzyloxycarbonyl)-3-N-(trifluoroacetyl)kanamycin A
• Synonyms: 3,6'-bis(N-benzyloxycarbonyl)-3-N-(trifluoroacetyl)kanamycin A
• CAS NO: 74256-73-8
• Molecular Weight: 848.782
• Mol File: 74256-73-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3,6'-bis(N-benzyloxycarbonyl)-3-N-(trifluoroacetyl)kanamycin A(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6'-bis(N-benzyloxycarbonyl)-3-N-(trifluoroacetyl)kanamycin A(74256-73-8)
• EPA Substance Registry System: 3,6'-bis(N-benzyloxycarbonyl)-3-N-(trifluoroacetyl)kanamycin A(74256-73-8)

Safety Data

• Hazardous Substances Data: 74256-73-8(Hazardous Substances Data)

Upstream product

• 59-01-8 kanamycin A 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 

Downstream Products

• 87508-29-0 1,3,6',3-tetrakis(N-t-butyloxycarbonyl)1-epikanamycin A 
• 59-01-8 kanamycin A 
• 80860-34-0 di-tert-butyl ((1S,3R,4S,5R,6R)-4-(((2S,3R,4S,5S,6R)-4-((tert-butoxycarbonyl)amino)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5S,6R)-6-(((tert-butoxycarbonyl)amino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)dicarbamate 
• 81076-65-5 1-epi-kanamycin A 
• 533923-37-4 C₄₉H₆₂F₃N₅O₂₁ 

Relevant articles and documents

Covalently linked kanamycin – Ciprofloxacin hybrid antibiotics as a tool to fight bacterial resistance

To address the growing problem of antibiotic resistance, a set of 12 hybrid compounds that covalently link fluoroquinolone (ciprofloxacin) and aminoglycoside (kanamycin A) antibiotics were synthesized, and their activity was determined against both Gram-n

Probing the functional requirements of the L-haba side-chain of amikacin - Synthesis, 16S A-site rRNA binding, and antibacterial activity

The l-amino group in amikacin was acylated with a variety of 2-hydroxy aminocarboxylic acids to probe the effect of acylation on ribosomal binding and antibacterial activity. The N-hydroxy urea analogue of amikacin (8a) in which the 2-S-hydroxyl-bearing carbon was replaced by an N-OH group was equally active against S. aureus and E. coli in vitro. The analogous tobramycin variant 9 was more active than amikacin.